Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin in Recurrent Glioblastoma
NCT02014844Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Mar 2014
- Primary completion
- Dec 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldoxorubicin in glioblastoma (GBM), sponsored by ImmunityBio, Inc.. Started Mar 2014; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02014844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014844.